Cargando…

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

Homologous recombination (HR) repair deficiency impairs the proper maintenance of genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1). Inhibitors of nuclear PARPs are effective therapeutics for a numbe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dae-Seok, Camacho, Cristel V., Kraus, W. Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080675/
https://www.ncbi.nlm.nih.gov/pubmed/33487630
http://dx.doi.org/10.1038/s12276-021-00557-3
_version_ 1783685483916689408
author Kim, Dae-Seok
Camacho, Cristel V.
Kraus, W. Lee
author_facet Kim, Dae-Seok
Camacho, Cristel V.
Kraus, W. Lee
author_sort Kim, Dae-Seok
collection PubMed
description Homologous recombination (HR) repair deficiency impairs the proper maintenance of genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1). Inhibitors of nuclear PARPs are effective therapeutics for a number of different types of cancers. Here we review key concepts and current progress on the therapeutic use of PARP inhibitors (PARPi). PARPi selectively induce synthetic lethality in cancer cells with homologous recombination deficiencies (HRDs), the most notable being cancer cells harboring mutations in the BRCA1 and BRCA2 genes. Recent clinical evidence, however, shows that PARPi can be effective as cancer therapeutics regardless of BRCA1/2 or HRD status, suggesting that a broader population of patients might benefit from PARPi therapy. Currently, four PARPi have been approved by the Food and Drug Administration (FDA) for the treatment of advanced ovarian and breast cancer with deleterious BRCA mutations. Although PARPi have been shown to improve progression-free survival, cancer cells inevitably develop resistance, which poses a significant obstacle to the prolonged use of PARP inhibitors. For example, somatic BRCA1/2 reversion mutations are often identified in patients with BRCA1/2-mutated cancers after treatment with platinum-based therapy, causing restoration of HR capacity and thus conferring PARPi resistance. Accordingly, PARPi have been studied in combination with other targeted therapies to overcome PARPi resistance, enhance PARPi efficacy, and sensitize tumors to PARP inhibition. Moreover, multiple clinical trials are now actively underway to evaluate novel combinations of PARPi with other anticancer therapies for the treatment of PARPi-resistant cancer. In this review, we highlight the mechanisms of action of PARP inhibitors with or without BRCA1/2 defects and provide an overview of the ongoing clinical trials of PARPi. We also review the current progress on PARPi-based combination strategies and PARP inhibitor resistance.
format Online
Article
Text
id pubmed-8080675
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80806752021-04-29 Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance Kim, Dae-Seok Camacho, Cristel V. Kraus, W. Lee Exp Mol Med Review Article Homologous recombination (HR) repair deficiency impairs the proper maintenance of genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1). Inhibitors of nuclear PARPs are effective therapeutics for a number of different types of cancers. Here we review key concepts and current progress on the therapeutic use of PARP inhibitors (PARPi). PARPi selectively induce synthetic lethality in cancer cells with homologous recombination deficiencies (HRDs), the most notable being cancer cells harboring mutations in the BRCA1 and BRCA2 genes. Recent clinical evidence, however, shows that PARPi can be effective as cancer therapeutics regardless of BRCA1/2 or HRD status, suggesting that a broader population of patients might benefit from PARPi therapy. Currently, four PARPi have been approved by the Food and Drug Administration (FDA) for the treatment of advanced ovarian and breast cancer with deleterious BRCA mutations. Although PARPi have been shown to improve progression-free survival, cancer cells inevitably develop resistance, which poses a significant obstacle to the prolonged use of PARP inhibitors. For example, somatic BRCA1/2 reversion mutations are often identified in patients with BRCA1/2-mutated cancers after treatment with platinum-based therapy, causing restoration of HR capacity and thus conferring PARPi resistance. Accordingly, PARPi have been studied in combination with other targeted therapies to overcome PARPi resistance, enhance PARPi efficacy, and sensitize tumors to PARP inhibition. Moreover, multiple clinical trials are now actively underway to evaluate novel combinations of PARPi with other anticancer therapies for the treatment of PARPi-resistant cancer. In this review, we highlight the mechanisms of action of PARP inhibitors with or without BRCA1/2 defects and provide an overview of the ongoing clinical trials of PARPi. We also review the current progress on PARPi-based combination strategies and PARP inhibitor resistance. Nature Publishing Group UK 2021-01-25 /pmc/articles/PMC8080675/ /pubmed/33487630 http://dx.doi.org/10.1038/s12276-021-00557-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Kim, Dae-Seok
Camacho, Cristel V.
Kraus, W. Lee
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
title Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
title_full Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
title_fullStr Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
title_full_unstemmed Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
title_short Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
title_sort alternate therapeutic pathways for parp inhibitors and potential mechanisms of resistance
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080675/
https://www.ncbi.nlm.nih.gov/pubmed/33487630
http://dx.doi.org/10.1038/s12276-021-00557-3
work_keys_str_mv AT kimdaeseok alternatetherapeuticpathwaysforparpinhibitorsandpotentialmechanismsofresistance
AT camachocristelv alternatetherapeuticpathwaysforparpinhibitorsandpotentialmechanismsofresistance
AT krauswlee alternatetherapeuticpathwaysforparpinhibitorsandpotentialmechanismsofresistance